SLC3A2 and neoplasm: One inhibitor that has shown a favorable safety profile and modest evidence of anti-tumor activity in phase I clinical trial for acute myeloid leukemia (NCT02040506) is IGN523, a humanized anti-CD98 (anti-SLC3A2) monoclonal antibody (89).